Skip to content

Clinical trials

Phase 2 Carcinoma, Renal Cell trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Renal Cell Phase: Phase 2 Clear all

594 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200011
200115
200214
200315
200427
200527
200631
200738
200828
200921
201015
201121
201218
201312
201412
201512
201623
201724
201823
201920
202023
202115
202220
202324
202416
202525
202629

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed275
Terminated105
Recruiting62
Unknown status62
Active, not recruiting41
Withdrawn24
Not yet recruiting20
Suspended3
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)58
M.D. Anderson Cancer Center32
Memorial Sloan Kettering Cancer Center14
Bayer10
Case Comprehensive Cancer Center10
Pfizer10
Novartis Pharmaceuticals9
City of Hope Medical Center7
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano6
Fudan University6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Renal Cell594
Kidney Neoplasms181
Neoplasm Metastasis60
Melanoma52
Carcinoma, Non-Small-Cell Lung35
Neoplasms32
Breast Neoplasms15
Carcinoma, Hepatocellular15
Carcinoma, Transitional Cell13
Colorectal Neoplasms13

Trials

Showing 51 to 75 of 594. Each trial links to its page on Pharma Observatory.

494 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.